Background: There is a pressing need for robust longitudinal cohort studies in the modern treatment era of multiple sclerosis.
Introduction
Although significant advances have been made in targeting the relapsing phase of multiple sclerosis (MS), fundamental questions remain about the pathophysiologic basis of its long-term course. For most individuals with early MS, the outcomes of interest-accumulation of disability and evolution from a relapsing to a progressive phase-require a decade or longer to become apparent. Many insights have been gained from previous natural history studies. [1] [2] [3] [4] [5] [6] [7] [8] [9] A poorer long-term outcome was associated with male sex, [1] [2] [3] 5, 8 older age at onset, [1] [2] [3] 5, 6, 8, 9 symptom location at initial presentation, 1, 2, 8, 9 number and pattern of attacks, [1] [2] [3] 5, 6, 8, 9 incomplete recovery from the first relapse, [1] [2] [3] and progressive versus relapsing symptoms from onset. [1] [2] [3] 5, 6, 8, 9 These natural history studies did not include advanced biomarkers such as magnetic resonance imaging (MRI) metrics (which have come to play a substantial role) 10 or genetics, and the identified risk factors for long-term outcomes were neither sufficiently sensitive nor specific to be useful for individual decision-making regarding disease-modifying therapies (DMTs). Most product registration trials are restricted to individual drugs (some use active comparators) and generally do not have systematic follow-up beyond 2-3 years. 11 Moreover, these studies provide little guidance in determining which agent to use initially, how to monitor efficacy, or when and how to switch treatments. In the real world, patients are often treated with multiple therapies sequentially and occasionally in combination. Cause and effect relationships can best be determined through prospective studies, and many of the most pressing questions in MS today cannot be answered by industry-sponsored clinical trials. There are relatively few prospective, observational cohort studies in the current treatment era, and most studies are relatively small, single-center, and retrospective. [12] [13] [14] A notable exception is MSBase, a longitudinal multi-center international registry of over 15,000 individuals with MS 15 that has provided a number of important insights relating to disease course; however, MRI and biomarkers are not collected. 16 The key to better understanding and eventually slowing or preventing MS disability is to develop a much more sophisticated understanding of disease progression as it applies to individual patients, with the ultimate goal of being able to tailor treatment in a precise, evidencebased, manner. One strategy to achieve this goal is to investigate long-term, deeply phenotyped cohorts from multiple centers to achieve adequate statistical power to answer this pressing question. Harmonization of data capture is essential in order to compare and contrast disease behavior across cohorts and to move beyond local prescribing patterns, environmental exposures (ultraviolet (UV), pathogens), or patient demographics (ancestry, smoking, diet) to understand other key contributors of disease progression.
Here, we introduce the Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT), a prospectively ascertained multi-center international cohort with over a decade of systematic follow-up. We illustrate the main advantages of this prospective cohort, including deep phenotyping, long-term follow-up, and an efficient structure for discovery/validation analyses. We then provide a roadmap for establishing a suite of research and data management tools that will enable us to address many questions related to disability and progression. An important outcome of this program will be its ability to share these emerging resources so that others can contribute to SUMMIT and use its infrastructure to address their own questions regarding MS. 17 a preexisting collaboration among University of California, San Francisco (UCSF's) Expression/genomics, Proteomics, Imaging, and Clinical (EPIC) cohort, Basel and Amsterdam), aligned to design and test a collaborative structure and methodology to study factors related to MS progression. Through this, they developed a shared framework for integrating and analyzing clinical, MRI, blood-based, and genomic data on existing MS patients and a plan to expand and improve upon this approach via collaborative development of new prospective patient cohorts. Given shared principles, scientific endeavors, and cohort design, two additional academic MS Centers have joined this collaboration: the Barcelona clinically isolated syndrome (CIS) cohort (Cemcat) and the more recent Beirut cohort (AUBMC-Multiple Sclerosis Interdisciplinary Research (AMIR)).
Methods

Cohorts
Boston. The CLIMB is a single-center prospective study that has enrolled more than 2100 patients since the year 2000 (www.climbstudy.org). 18 Patients are recruited directly from the clinical practice (median: 1 year since symptom onset) and followed longitudinally with standardized clinical exams every 6 months, and annual MRIs and stored blood samples. Within this umbrella, a subset of patients is enrolled in more detailed studies, including quality of life (QOL) and genetics studies. CLIMB patients' clinical and neuroimaging measures, while standardized, are derived from routine clinical care. Overall, the dropout rate in CLIMB in 3% per year and is largely due to patients moving or the patient's physician leaving the practice.
From all CLIMB participants, we selected for inclusion into the CLIMB-SUMMIT cohort adult participants with a diagnosis of MS meeting 2010 International Panel criteria, 19 who were recruited into the QOL arm of the CLIMB study (enrolled between 4 May 2000 and 9 March 2013) or those CLIMB subjects who had 10 years of follow-up since first symptom. 20 or CIS if fulfilling three of the four Barkhof criteria for dissemination in space and Expanded Disability Status Scale (EDSS) 0-7.5, were included. In 2011, new patients were added to compensate for drop outs of the initial study, comprising a total of 289. MS history, demographics, and exposures were collected at baseline. Patients receive annual clinical examinations including relapse history and EDSS, Symbol Digit Modalities Test (SDMT), and multiple sclerosis functional composite (MSFC) assessments, as well as MRIs and blood sampling (serum and plasma). The follow-up time for the original cohort is more than 10 years and for patients recruited after 2011 is up to 6 years. Drop-out rates for the since 2011 were 10% in the first year, 7% in year 1, and 2% after year 2.
Amsterdam. The cohort of the MS Center Amsterdam (MSCA) selected for SUMMIT is a single-center longitudinal prospective inception cohort of MS patients included within a year from diagnosis of MS according to the 2010 International Panel criteria. 19 All patients were intensively followed up for 4 years using questionnaires, neurological evaluations, extensive testing, and MRI scans. Subsequently, patients were assessed at years 6 and 11. At the end of 2017, collection of year 11 data will be finished with a retention of 92%.
Barcelona. The Barcelona CIS cohort is a singlecenter prospective open cohort initiated in 1995. It includes patients aged under 50 years of age with a CIS suggestive of central nervous system demyelination not attributable to other diseases and with onset of symptoms within 3 months of the first clinical evaluation at the Cemcat MS center. Patients are regularly followed on a biannual basis following a pre-defined clinical and MRI protocol. CIS topography, use of steroids, and EDSS assessment are evaluated. IgG oligoclonal bands (OB) are examined within the first 3 months of disease onset. The remaining serum and cerebrospinal fluid (CSF) samples are stored at −80°C. Brain MRI is performed 3-5 months after the CIS and repeated after 12 months and every 5 years. MRI is performed on a 1.5-or 3.0-T magnet with a standard head coil. MR analysis is routinely performed by one of two neuroradiologists with expertise in inflammatory demyelinating diseases. Overall, the dropout rate in the Barcelona CIS cohort is 3.2% per year. 22 Beirut. The AMIR is a single-center longitudinal prospective study that has enrolled 891 patients since 2012. Patients are recruited directly from the clinical practice and followed longitudinally with standardized clinical exams every 6 months, annual or biannual MRIs, and QOL questionnaires. Most patients opt to participate in the blood, DNA, and urine biobank (annual collection). Patients may also participate in longitudinal optical coherence tomography (OCT) yearly measurements. Patients with all forms of MS (including CIS, radiologically isolated syndrome (RIS)) and with neuromyelitis optica (NMO) are included in this cohort.
As outlined in Table 1 , each cohort has distinct features in terms of subject selection and depth of phenotyping; nonetheless, there is consistency in primary MS-related data elements. Data harmonization between the UCSF and BWH cohorts has been completed and is ongoing with the other cohorts. For this reason, we will focus below how on two of these cohorts, BWH and UCSF, offer complementary and synergistic approaches to understanding the course of MS in the modern era. The Committee on Human Research at each institution approved the SUMMIT protocol, and informed consent was obtained from all participants. Detailed information about the methods deployed for each illustrative project are provided in Appendix 1 and about study retention and data completeness is provided in Appendix 2.
Results
Illustrative projects
Is the course of MS becoming milder? Clinical features in two modern cohorts. Whether due to earlier diagnosis, evolving diagnostic criteria that now include MRI, rapid initiation of DMTs, inclusion of milder forms of MS, or other environmental/epigenetic phenomena, it has been hypothesized that MS now appears to have an overall milder course than in the pre-treatment era. 7, 23 To address this question, we included all SUMMIT participants. Using simple descriptive statistics, we compared demographic and clinical features at the Table 1 . Prospective data collection across the SUMMIT cohorts. Study retention 3% attrition rate per year 91% retention rate (incl. follow-up on deceased); 450 currently being followed for YR12 While at baseline, most participants in both cohorts were treated with first-line injectable therapies, at the most recent clinical visit, there was a broader distribution of therapies, reflecting a general transition to oral therapies in CLIMB contrasted with a "treat to target" approach (i.e. advancing therapy based on evidence of disease activity) in EPIC. These differences in practice patterns highlight the benefits of being able to seize on patterns from one cohort to prospectively examine differences in another.
Our next goal was to examine aspects of disability progression in a contemporary clinical setting. We used an interval-censored approach for estimating time to sustaining EDSS score of 6 24 ( Figure 1 ) and secondarily to sustained EDSS of 3, in all SUMMIT participants. The proportion of EPIC participants sustaining EDSS 3 by 15 years was 42% (56% by 20 years; 67% by 25 years). The proportion of subjects in CLIMB sustaining EDSS 3 by 15 years was 39% (50% by 20 years; 59% by 25 years). The proportion of subjects in EPIC sustaining EDSS 6 by 15 years was 10% (13% by 20 years; 17% by 25 years). In CLIMB, the proportion of subjects sustaining EDSS 6 by 15 years was 15% (22% by 20 years; 27% by 25 years). In both cohorts, disability accumulation was less pronounced than in earlier natural history studies, where up to 50% of the cohort had reached an EDSS 6 by 15-16 years. 3, 25 Overall, the EPIC and CLIMB cohorts are similar at present in demographic and disease characteristics. Furthermore, while both cohorts showed a slower time to EDSS 6 than previously reported in natural history studies, the small differences between the two cohorts provide fertile ground for future detailed work on environmental, genomic, and pharmacological contributors to disability progression.
Harmonizing MRI data to evaluate the utility of no evidence of disease activity in predicting long-term disease progression. The concept of "no evidence of disease activity" (NEDA) has been gaining traction as a goal of DMT management in relapsing forms of MS, and yet its utility in predicting longterm outcomes is uncertain. 26 Both sites previously reported NEDA analyses, 21, 27 with divergent findings: in the BWH cohort, NEDA (clinical + MRI) at 2 years had a positive predictive value of 78.3% for no progression (EDSS score change ⩽0.5) at 7 years; 27 while in EPIC, participants meeting NEDA (clinical + MRI) at 2 years had long-term outcomes at 10 years that were no different from those of the cohort as a whole. 21 We piloted our ability to evaluate the long-term predictive utility of NEDA using our cohorts. First, we compared the rate of clinical NEDA (no relapses and no clinically significant increase in EDSS from baseline through the second year of the study) over 2 years in both cohorts. In CLIMB, 186 (56%) of 335 subjects fulfilled clinical NEDA criteria, as did 214 (55%) of 390 EPIC participants (p = 0.88).
Then, we piloted our ability to apply a common clinical and MRI data processing methodology in a subset of 43 bout-onset individuals in each cohort, matched for age (39.6 years), sex (72.1% female), disease duration (3 years), and disease course (9.3% CIS; 90.7% relapsing-remitting multiple sclerosis (RRMS)) ( Table 3 ). In the pooled cohort, 37% subjects satisfied clinical NEDA, and 11% satisfied both clinical + MRI NEDA. Clinical + MRI NEDA at 2 years was not predictive of changes in EDSS between years 2 and 10 (p = 1.0). This pilot finding with low numbers will require validation in the entire cohort. Using a newly developed MRI database and common image processing pipeline, the project will include all 511 CLIMB and 517 EPIC subjects, providing an opportunity to examine the impact of the newly described NEDA-4 metric, 28 which adds a brain atrophy change metric to the traditional NEDA assessments.
Furthermore, for prospective collection of MRI data, the scanners (3T Skyra; Siemens Healthcare, Erlangen, Germany) and acquisition protocols at the two sites have been harmonized. The two sites share three identical core sequences (3D T2, fluid-attenuated inversion recovery, and T1-weighted gradientecho acquisitions) and have furthermore completed human phantom calibration studies that enable calibration of regional volumes in MS patients across the sites. 29 Harmonizing genetic data to better understand MS risk. Both sites have a long history of productive collaborations on major MS genetics efforts including participation in the International MS Genetics For normally distributed data, mean and standard deviation are shown, and Student's t-test was used. For data that are not normally distributed, median, interquartile, and range are shown, and Wilcoxon test was used. For qualitative data, counts and percentages are shown, and Fisher's exact test was used. a DMT first-line treatments include interferons (Avonex, Betaseron, Extavia, Rebif, and Plegridy) and glatiramer acetate (Copaxone, Glatopa). DMT high treatments include Campath, natalizumab, ocrelizumab, alemtuzumab, and Novantrone. DMT oral treatments include fingolimod, dimethyl fumarate, and teriflunomide. Experimental treatments include Cladribine, doxycycline, MBP8298, Minocycline, T cell vaccination study, T-cell receptor (TCR) peptide trial, low-dose Naltrexone, Biotin, CTLA4-Ig, Orencia, Rapamune, Rilutek, Simulect, Zenapax, and Ozanimod. Immune treatments include intravenous immune globulin (IVIG) and plasmapheresis. MS other treatments include rituximab, chemotherapy, cyclophosphamide, Cellcept, Methotrexate, Imuran, and Ciclosporin. Steroid treatments include oral steroids, intravenous steroids, intravenous methylprednisolone, dexamethasone, prednisolone, prednisone, adrenocorticotropic hormone (ACTH), hydrocortisone, and test Steroid.
To illustrate the wealth of data and the value of efficient discovery/replication analyses, we assessed genetic risk markers in a subset of 1014 BWH subjects (including 248 subjects from the CLIMB-SUMMIT group who had genotyping available) and 467 EPIC subjects. We focused on two genetic measures: (1) the rs3129889 SNP, which captures the HLA DRB1*1501 MS susceptibility haplotype, is associated with an earlier age at MS onset 32, 34, 35 and (2) a genetic risk score integrating the effect of 95 susceptibility alleles (GRS95) outside of the major histocompatibility complex. 36 We asked whether (1) the two cohorts differed in terms of genetic risk burden; (2) given established sex-based differences in MS risk, there might be similar differences in the distribution of genetic measures by gender; and (3) the GRS95, in addition to HLA-DRB1*15:01, was associated with age at initial MS symptom. The details of the genotyping are summarized in the supplementary materials.
As shown in Table 4 , the cohorts were not significantly different in terms of the frequency of individuals carrying the HLA DRB1*1501 risk haplotype or in the mean GRS95. Women had a higher mean HLA DRB1*1501 score than men (in each cohort, as well as the pooled analysis where p = 0.0012) but a lower non-HLA GRS95 (true in EPIC (p = 0.029) and in the pooled analysis (p = 0.023)). Finally, with respect to age at MS onset, HLA DRB1*1501 was associated with earlier MS onset in the pooled analysis (p = 0.0011). Age of onset was not significant for GRS95 (p = 0.10).
Altogether, we were able to support a previously reported association between the HLA DRB1*1501 allele with an earlier age of MS onset 37 in these two cohorts. More interestingly, we were able to apply a discovery/replication model to validate sex differences in genetic measures. Our findings highlight the value of sex-stratified genetic analyses and genetic risk scores in future genotype-phenotype studies in MS. 38 Toward a universal data repository. Our vision for the SUMMIT project is to create an open network, through which scientists would contribute to, and have access to, de-identified high-quality, deeply profiled, prospectively collected data. By analogy, the SUMMIT concept shares attributes with the open access Alzheimer's 39 or to the seminal, but population-based, Framingham Heart Study 40,41 which enabled its founding investigators, and subsequently many others, to understand chronic heart disease in defined cohorts of patients over long periods of time. One important difference of the SUMMIT model is the requirement that external investigators obtain datasets from the SUM-MIT Data Coordinating Center, after review of their scientific proposal. In MS, the MSBase registry has provided a number of important insights relating to disease course, but MRIs and biomarker data are not collected in the registry. 16 What distinguishes SUMMIT from major clinical trial cohorts in MS, of similar cohort size, is its (1) longer duration of follow-up; (2) inclusion of all MS phenotypes (CIS, RRMS, primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS)); (3) ascertainment of clinical metrics that extend beyond the EDSS, plus collection of genomics and other biomarkers; (4) scope of the questions that will be addressed; and (5) the opportunity for discovery and validation of biomarkers in two distinct cohorts.
Common platform
Our first goal was to fully integrate the clinical, imaging, and biomarker data from the two centers into a common informatics platform capable of tracking, synthesizing, and analyzing data. Several principles are paramount, including the development of rules for sharing finite resources (e.g. CSF or cells); insuring privacy protection for participants, as well as the capability to remove data from those who wish to withdraw from participation; and creating a long-term governance structure for the maintenance, expansion, and beneficent use of SUMMIT resources that can function beyond the tenure of its founders (included in Supplementary Materials). To ensure the judicious use of finite biosamples, our Biorepository Governance Committee has the primary responsibility to design and execute appropriate studies using the material available. Their decisions will be based on a sound biological rationale, proper statistical handling, and expert execution. The Committee also has the responsibility of evaluating external requests for biosamples. Some collected materials in the repository, such as DNA, are abundant while others, such as serum, plasma, and RNA, are in limited supply.
Sequential expansion into an open access platform
This network is sequentially expanding along a multistage process to include other academic centers with the ability to add prospectively followed patients into the system. We will share all of the relevant protocols and invite other MS investigators to upload comparable data from their own patients. Ultimately, this would involve direct online data entry from both large and small MS centers that wish to contribute to the dataset, creating a community-wide resource. We have generated the following criteria for inclusion of a new Center into SUMMIT: (1) prospective data collection with visits at least annually; (2) contribution of at least 50 new participants a year, or a total of 300 participants from onset; (3) contribution of at least clinical and MRI data meeting basic feature list as detailed in Table 1 ; (4) institutionally approved informed consent forms indicating participant approval that anonymized data be shared outside of the home institution; (5) clearly identified site principal investigator, as well as clinical, MRI, and data lead investigators; and (6) approval by the SUMMIT Governance Group.
Conclusion
In summary, the SUMMIT cohort combines the ongoing efforts of several large referral centers to create a uniform deeply characterized cohort of thousands of patients followed for an extended period of time. Built into the program are independent validation cohorts to ensure the accuracy and generalizability of the findings; to capture any heterogeneity between sites in terms of individual practice patterns, environmental exposures, and ancestry; and to rapidly apply novel diagnostic markers, including newly developed imaging sequences, as these become available.
In addition to ongoing augmentation of the SUMMIT cohorts at the two North American sites (BWH and UCSF), the addition of new centers to the SUMMIT consortium is in progress. This growth will align a global group of MS centers with proven records of effective collaboration to create the most rigorous long-term cohort possible for open use by the global research community. These centers will benefit from the existing prototype platform for managing, accessing, and displaying multi-dimensional patient information. Importantly, additional cohorts would also capture broader racial/ethnic diversity, as well as differences in management (including prescribing patterns).
In the near future, our independent cohorts should provide the much-needed statistical power to evaluate new biomarkers and therapies, particularly with respect to their long-term implications. In the domain of disease prediction, this will include validating existing biomarkers, such as transcription factor Tob1 42 (previously reported as marking the transition from CIS to RRMS), 43 a transcriptional (MS A /MS B ) signature from peripheral blood mononuclear cells, 44 or lipid antibodies from antigen arrays, 45 among others. It will also promote adoption of new serum markers (such as circulating microRNA (miRNA), 46 with messenger RNA (mRNA) targets integrated into biologically meaningful pathways) and emerging MRI sequences (such as quantitation of regional brain, 47 ,48 gray matter, 45, [49] [50] [51] and spinal cord atrophy 52, 53 ) that show stronger associations with subsequent disability than traditional measurement of white matter burden. For example, an efficient phase-sensitive inversion recovery method termed SF-SIGMA has now been implemented at both sites, permitting automated segmentation of spinal cord gray matter 54, 55 shown to be the strongest MRI predictor yet developed for MS disability. 56, 57 In the domain of disease treatment, combining fully harmonized, deeply phenotyped, long-term cohorts will provide power to analyze the impact of a variety of therapies (including therapies which are not U.S. Food and Drug Administration (FDA)-approved for MS) on clinical progression outside of the structure of trial-based cohorts. It should also be possible to monitor adherence to DMTs (likely lower in real-world settings than in clinical trials) and assess its effect on disease progression. Also, the current practice, supported by many payers, to promote step-up therapies rather than aggressive therapies in the initial management of early MS, makes the current SUMMIT cohort an ideal platform to study this "real-world" question. Assessing the value of diagnostic and monitoring tools, including costly imaging studies, on the longterm management of established MS could be another objective. Finally, these robust primary data will also advance development of evidence-based precision medicine and individualized care for the MS patient, through new areas of inquiry such as bioinformatics, machine-learning tools, user-friendly dashboards, 58 and remote medicine.
Novel analyses that combine longitudinal clinical and MRI information along with biomarker and genomic (including pharmacogenomic) data enabled by the SUMMIT database and repositories will enable investigators worldwide to access robust primary data to address critical questions about long-term progression of disease and ask new sets of questions as the dynamic landscape of MS prevention and management continues to evolve. 
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